Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec and Galapagos have announced a global collaboration focused on a novel target for fibrosis and other indications.
Image: Evotec and Galapagos have entered into collaboration in fibrosis field. Photo: courtesy of ranjith ravindran / FreeDigitalPhotos.net.
Subscribe to our email newsletter
The collaboration concerns a small molecule programme, currently in pre-clinical development for the treatment of fibrotic diseases of the liver and other organs. The target has been identified and validated using Evotec’s proprietary platforms for fibrotic diseases and NASH.
Evotec utilised its in-house assay development and drug screening capabilities to identify small molecule modulators against the target, which remains undisclosed.
In exchange for global commercialisation rights to Galapagos, Evotec receives an upfront payment and is eligible for potential milestone and royalty payments. Galapagos will be responsible for all further development of the programme. Furthermore, Galapagos will have access to specific screening formats at Evotec to support the final pre-clinical development.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are delighted to be working with Galapagos on this innovative project in an area of high unmet medical need. The team at Galapagos share our focus on novel, first-in-class therapeutic candidates and we are glad to be part of their portfolio building.”
“Following the Fibrocor deal announced early January, the collaboration with Evotec announced today again underlines our commitment to expanding our fibrosis franchise”, said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos. “We highly regard the scientific know-how of Evotec, and are hence very much looking forward to collaborating with the team.”
Galapagos discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases.
Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines.
Source: Company Press Release
